Summary and Discussion - First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness - NCBI Bookshelf
This report provides a comprehensive synthesis of the evidence on the comparative effectiveness and safety of first- (FGAs) versus second-generation antipsychotics (SGAs) in adults with schizophrenia, schizophrenia-related psychoses, and bipolar disorder. We included studies that directly compared one FGA versus one SGA. We did not include: studies comparing various FGAs or those comparing various SGAs; trials with no active comparator (e.g., no treatment or placebo-controlled trials); or those trials comparing antipsychotics not approved by the U.S. Food and Drug Administration (FDA) or no longer available in the U.S. (Appendix O). The strength of evidence (SoE) for core illness symptoms and key adverse events (AEs) is summarized by comparison in the tables below.

Who Voted

Leave a comment